TITLE

RISK ASSESSMENT AND MANAGEMENT OF METABOLIC SYNDROME DUE TO ANTIPSYCHOTIC MEDICATION

AUTHOR(S)
Miulescu, Rucsandra Dӑnciulescu; Muşat, Mӑdalina; Dӑnoiu, Suzana; Poianӑ, Cӑtӑlina; Dumitrache, C.
PUB. DATE
September 2009
SOURCE
Therapeutics, Pharmacology & Clinical Toxicology;2009, Vol. 13 Issue 3, p315
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The metabolic syndrome is comprised of several cardiovascular risk factors such as central obesity, hyperglycemia, hypertension and hyperlipidemia, most probably pathogenically correlated. Patients with schizophrenia have an increased risk of developing metabolic syndrome due to inappropriate physical activity, disorders of food intake or secondary to antipsychotic medication. Due to the increased prevalence of metabolic syndrome and diabetes mellitus in patients with schizophrenia, the American Association of Psychiatry recommends screening and follow-up for metabolic risk factors. Thus the recommendation is to assess fasting glycemia and glycated hemoglobin at 4 month s from commencement of a new drug therapy, then annually. BMI has to be monitored every 3 to 6 month s. Except for the patients with a BMI below 18.5, every increment of their BMI of 1kg/m2 should be followed by either a change in antipsychotic medication or the admission of the patient in a weight control program.
ACCESSION #
50339700

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics